NKNadezhda A. Komelyagina

Nadezhda A. Komelyagina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nadezhda A. Komelyagina has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The importance of immunological monitoring in the treatment of refractory membranous nephropathy: clinical case

    by S. I. Kudryashov, L. M. Karzakova, M. Al. Stenina, N. A. Komelyagina

    Primary membranous nephropathy is the most common morphological variant of glomerulonephritis with nephrotic syndrome in the European ancestry. Immunosuppressive therapy is required in most cases of membranous nephropathy treatment. The choice of immunosuppressive drugs and the determination of therapy duration for this nephropathy cause significant difficulties. The role of monitoring immunological parameters in assessing the effectiveness of immunosuppressive therapy and its duration has been poorly studied. The clinical case report examines modern treatment methods for membranous nephropathy with refractory nephrotic syndrome and demonstrates, using a concrete clinical example, the significance of monitoring immunological parameters during immunosuppressive therapy. A 62-year-old female patient had persistent edema of the lower extremities, as well as high levels of proteinuria and autoantibodies to phospholipase A2 receptor (PLA2R). The diagnosis of stage 2 membranous nephropathy was made based on the morphological findings of the renal biopsy. Initial treatment with corticosteroids resulted only in a short-term improvement. Adding cyclosporine to steroid therapy also failed to achieve stable remission of the disease. Two infusions of rituximab (1 g each) in combination with methylprednisolone (16 mg) led to partial remission of the disease by the fifth month (22 weeks later) after administration of the 2nd dose of rituximab, complete remission was achieved by the sixth month (27 weeks later). By this time, the levels of proteinuria and PLA2R antibodies had significantly decreased. However, monitoring of the B-system immune parameters showed increased urinary excretion of IgG and IgA, depending on the damage to the glomerular filtration barrier, which was the reason for the 3rd infusion of rituximab. Laboratory tests conducted 5 months after the administration of the 3rd dose of rituximab confirmed maintained clinical remission and restoration of immunoglobulin levels to the reference values. This clinical observation confirms that the use of rituximab in combination with methylprednisolone is an effective method of refractory membranous nephropathy treatment. This case report demonstrates the possibility of monitoring urinary IgG and IgA levels normalized to urine creatinine level to assess the effectiveness of rituximab therapy and determine its optimal duration.

  • THE EFFECT OF COVID-19 ON MYOCARDIAL DAMAGE: A CLINICAL CASE

    by Nadezhda V. Zhuravleva, Vadim E. Babokin, Elena V. Barsukova, Luiza M. Karzakova, Rosa V. Fomina, Nadezhda A. Komelyagina, Tatyana L. Smirnova, Kseniya I. Platonova, Nadezhda D. Ukhterova, Tatyana S. Lutkova, et al.

    Despite the fact that the general clinical manifestations of COVID-19 are well known, there remain problems associated with the impact of COVID-19 on human health, in addition to its effects on the respiratory system. Patients with COVID-19 and concomitant cardiovascular diseases are more likely to be hospitalized and to pass treatment in the intensive care units and to have worse prognoses. The article discusses the problems arising from the effect of type 2 coronavirus acute respiratory syndrome (SARS-CoV-2) on the cardiovascular system, starting with the mechanisms associated with angiotensin converting enzyme 2 (ACE2) receptors, as well as discusses cases of major pathological changes in the heart and blood vessels that are detected in these patients. In addition to the known risk factors for severe COVID-19: cardiovascular diseases, diabetes mellitus, chronic lung diseases and old age, even young patients without a history of risk factors may develop myocardial damage. We present a description of a clinical case of acute myocardial infarction against the background of a new coronavirus infection COVID-19 in a patient aged 28 years with a diagnosis of coronary heart disease.


  • Open Access

    Features of the immunological profile of blood and urine in patients with post-infectious glomerulonephritis

    by L. M. Karzakova, S. I. Kudryashov, L. V. Borisova, N. V. Zhuravleva, N. A. Komelyagina, A. V. Odintsova, I. A. Sidorov

    The timely diagnosis and treatment of post-infectious glomerulonephritis (PIGN) is currently limited by the erased and low-symptom nature of the disease, which leads to the search for informative biological markers of the disease, which can be used as immunological indicators of blood and urine. The study was carried out in order to establish the characteristic changes in the immunological parameters of blood and urine in patients with PIGN. The study included 60 patients with PIGN from among the patients, hospitalized in the nephrology department of the Republican Clinical Hospital of Health Care Ministry of the Chuvash Republic in 2015-2018. In addition to the generally accepted research methods, the patients underwent: 1) the determination of indicators of innate and acquired immune response in the blood (CD3+ -, CD3+ CD4+-, CD3+CD8+-, CD4+CD25+-, CD95+-, CD20+-, CD14+CD282+-, CD14+CD284+- cells; levels of IgG, IgA, IgM, circulating immune complexes, C3, C4) and urine (levels of IgG, IgA, IgM, C3, C4); 2) the determination of the levels of cytokines - IL-1β, Ra-IL-1β, IL-2, IL-4, IL-8, IL-10, IL-17A in blood serum and urine. The data obtained were compared with those of the group of healthy individuals. The changes in blood immunological parameters, identified in the group of patients with PIGN, indicate the activation of innate immunity (the increase in the number of CD14+TLR2+- cells) and the humoral component of adaptive immunity (the increase in the number of B-lymphocytes, hyperimmunoglobulinemia - the increase in IgM and IgA levels) against the background of the decrease in the number of T (CD3+) - lymphocytes and regulatory (CD4+CD25high) - cells, hypocomplementemia (decreased levels of C3, C4). The increase in the content of C3, IgG and IgA was found in the urine. The cytokine profile of blood in patients with PIGN was characterized by the increase in the levels of pro- and anti-inflammatory cytokines IL-1β, Ra-IL-1β, IL-2, IL-8, IL-10, IL-17A, with the exception of IL-4, which remained on the levels of healthy individuals. The cytokine profile of urine in patients was characterized by the increase in the levels of pro-inflammatory cytokines IL-1β, IL-2, IL-8, IL-17A and anti-inflammatory cytokine - IL-10, with no changes in the content of Ra-IL-1β and IL-4. The revealed features of the immunological profile of blood and urine in patients with PIGN reflect the immunopathogenetic mechanisms of this disease.


  • MODERN APPROACHES TO THE DIAGNOSIS AND THERAPY OF ALLERGIC DISEASES

    by Tatyana S. Lutkova, Luiza M. Karzakova, Nadezhda V. Zhuravleva, Nataliya P. Andreeva, Nadezhda D. Ukhterova, Nadezhda A. Komelyagina, Elvira S. Gavrilova, Sergei I. Kudryashov

    Currently, great efforts are being made to optimize diagnostic and therapeutic standards in allergology. The introduction of biological drugs (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab) into clinical practice increases the need for biomarkers of allergic diseases that make it possible to adequately choose a treatment regimen, determine the duration of therapy with expensive biopreparations. The article discusses the possibilities of using biomarkers developed in recent years thanks to the so-called "omics" technologies in clinical practice. Biomarkers used for the diagnosis and treatment of bronchial asthma, atopic dermatitis, allergic rhinitis, food allergies, hypersensitivity to drugs, as well as for evaluating the effectiveness of allergen – specific immunotherapy are considered. The introduction of biomarkers into clinical practice has made it possible to carry out endotyping of some allergic diseases, which opens up prospects for new approaches to classification of these diseases, development of individual treatment targets and indications for administering personalized therapy. Endotyping of diseases is expected to be transferred to the category of diagnostic tests. However, it is necessary to overcome a number of problems before the treatment based on endotype determination will be introduced into everyday practice in allergic diseases and bronchial asthma. Currently, most of the research on the endotyping of diseases is carried out in severe forms of allergic diseases. It is beyond argument that the best ways to treat allergic diseases will be found in the near future, with a therapeutic approach focused on a specific patient, taking into account the patient's wishes, the presence of contraindications, the psychological characteristics of the patient, his expected adherence to therapy and possible side effects.


  • Open Access

    About connection of clinical manifestations of glomerulonephritis with features of the thyroid status of patients

    by Louise M. Karzakova, Olga I. Avtonomova, Sergey I. Kudryashov, Nadezhda D. Ukhterova, Nadezhda А. Komelyagina, Кудряшов Сергей Игоревич

    BACKGROUND: There are four clinical variants of glomerulonephritis (GN) - urinary (latent), hypertensive, nephrotic and mixed. It was found that the features of clinical manifestations of GN that determine its clinical variant do not depend on the etiology, pathogenesis and morphological form of the disease. Taking into account the obtained data on the association of nephrotic syndrome with hypofunction of the thyroid gland, we suggested, that the formation of clinical variants of GN may be influenced by the features of the thyroid status of patients. AIM: Study the relationship of variants of clinical manifestations of GN with indicants of thyroid status. MATERIALS AND METHODS: The study included patients with primary GN who received in-treatment in the nephrology unit of a general hospital. Patients were selected into 4 groups depending on the clinical variant of GN (urinary, nephrotic, hypertensive and mixed variants). When selecting patients, we achieved comparability of groups by age, gender, morphological variants and duration of the disease. In addition to the generally accepted methods of research, patients were performed: 1) assessment of the thyroid status (thyroid-stimulating hormone (TSH), free thyroxine (free T4), free triiodothyronine (free T3), antibodies to thyroperoxidase (anti-TPO), (free T3+free T4)/TSH, free T4/free T3, free T4/TSH); 2) determination of levels of interleukin - IL-1, IL-4 and IL-10 in blood serum; 3) ultrasound (US) examination of the thyroid gland. The obtained data were compared with those of healthy people. RESULTS: The group of patients with the nephrotic variant of GN in 50% of cases showed a decrease of the level of free Т4 with the increase of TSH level, 26.7% showed a moderate increase of TSH at unchanged concentrations of free Т4 and free T3. In patients with the urinary variant of GN, the thyroid status did not differ from that in healthy patients, and the cytokine profile was characterized by a simultaneous increase in the content of the proinflammatory cytokine IL-1 and the anti-inflammatory cytokine IL-10. The group of patients with the hypertonic variant of GN in 82% of cases showed an isolated increase in TSH content. In the group of patients with a mixed variant of GN, changes in thyroid indices were predominant, combined with a large variability in the level of IL-1 production. CONCLUSIONS: The results of the study indicate the influence of the functional state of the pituitary-thyroid system on the formation of different clinical variants of GN, which depends mainly on the level of production of the anti-inflammatory cytokine IL-10.